This trial is active, not recruiting.

Condition lung diseases
Phase phase 2
Sponsor Tel-Aviv Sourasky Medical Center
Start date December 2009
End date September 2010
Trial size 70 participants
Trial identifier NCT01140685, TASMC-10-LF-669-CTIL


This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Primary Outcomes

exhaled CO levels
time frame: 2010-2011

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Male and female - Ages >/= 18 years - Diagnosed with one or more lung diseases - Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center

Additional Information

Principal investigator Elizabeth Fierman, PHD
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center.